GLP-2T research

The GLP-2T evidence base cited here is 7 sources — 4 clinical, 2 regulatory. Its strongest evidence is human — 4 clinical studies, most recently 2023 ("Tirzepatide Once Weekly for the Treatment of Obesity in People with Type…"). Regulatory status: FDA-approved (Mounjaro/Zepbound).

Cross-trial comparison only — populations, durations, and endpoints differ, and only GLP-2T vs GLP-1S has been tested head-to-head (SURPASS-2).

*GLP-3R's 28.7% figure is reported topline, pending peer-reviewed publication. See the GLP-3R and GLP-1S research pages for the full breakdowns. All three are built on the same His-Aib-Glu-Gly-Thr-Phe… N-terminal incretin backbone — what differs is the receptor targets (GLP-1 → +GIP → +glucagon), the fatty-acid chain and half-life (~7 / ~5 / ~6 days), and peak efficacy.

• GLP-2T is an FDA-approved dual GIP/GLP-1 receptor agonist from Eli Lilly, sold as Mounjaro (type 2 diabetes, 2022) and Zepbound (weight management, 2023; obstructive sleep apnea, 2024).
• It carries a boxed warning for thyroid C-cell tumors and is contraindicated in anyone with a personal/family history of medullary thyroid carcinoma or MEN 2.

Unlike GLP-3R (still investigational), GLP-2T is fully FDA-approved — as Mounjaro for type 2 diabetes, Zepbound for chronic weight management, and Zepbound for obstructive sleep apnea in adults with obesity. The clinical evidence base behind it is among the deepest of any peptide therapeutic.

GLP-2T is a synthetic 39-amino-acid peptide that binds and activates both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor — the two incretin hormones that govern after-meal insulin release, appetite, and energy balance.

Engaging both receptors produces additive and in some pathways synergistic effects on blood sugar and body weight that GLP-1 activation alone cannot match — the central reason it outperformed GLP-1S in direct comparison.

• Weeks 1–4: ~2–4% weight loss; appetite suppression often starts in week one
• Weeks 4–12: ~5–10% loss; glycemic improvements appear by weeks 4–8

• Metformin — the most common pairing in T2D; different mechanism, well tolerated.
• SGLT2 inhibitors (empagliflozin, dapagliflozin) — add ~2–3 kg of loss plus cardiorenal protection.
• Testosterone (in hypogonadal men) — may help preserve lean mass during rapid weight loss.

• Mounjaro — approved May 2022 for type 2 diabetes (adjunct to diet/exercise).
• Zepbound — approved Nov 2023 for chronic weight management (BMI ≥30, or ≥27 with a comorbidity).
• Zepbound (OSA) — approved 2024 for moderate-to-severe obstructive sleep apnea in adults with obesity (SURMOUNT-OSA).
• Compounded GLP-2T is increasingly restricted now that the shortage has resolved and the FDA is enforcing against copies of an approved drug.

Research-grade GLP-2T from peptide suppliers is for laboratory research only — not approved for human use outside a prescription.

As of 2026, GLP-1 agonists including GLP-2T are on WADA's monitoring program but not prohibited — there are no current sanctions for use. The monitoring status means it's being evaluated for possible future prohibition, so athletes should confirm the current year's list with their anti-doping authority and seek a TUE where a diagnosed condition applies.

On the Huberman Lab podcast, Dr. Abud Bakri used the GLP-1 class to make his central point that 'peptide' is a useless category: orforglipron (a non-peptide oral) is functionally closer to GLP-2T than BPC-157 (a peptide) is — what matters is the receptor, not the chemical class. GLP-2T's dual GIP + GLP-1 mechanism is what distinguishes it from GLP-1S.

He also surfaced economics most patients never hear: compounding markups are often pocketed by the prescribing clinician (a pharmacy may charge ~$150/vial while the patient is charged $200–$800), and patients are within their rights to ask what their provider paid. As with the whole class, his framing was cautious optimism plus an honest 'long-term unknown.'

Expert commentary on mechanism and on the market economics of compounded GLP-1s.

All citations link to the original source (PubMed, journal site, or regulatory filing). Independent research database — no vendor influence on what's cited.